Converge Bio, an innovative startup specializing in AI-driven drug discovery, has successfully raised $25 million in a Series A funding round. The investment was spearheaded by Bessemer Venture Partners, a well-known venture capital firm. Notably, the round also saw participation from high-profile executives from major tech companies including Meta, OpenAI, and Wiz, underscoring the growing interest in AI applications within the pharmaceutical sector. This influx of capital will enable Converge Bio to accelerate its research and development efforts, aiming to revolutionize the way new drugs are discovered and brought to market.